New Delhi, March 22 -- Alkem Laboratories is positioning itself to lead India's fast-growing weight-loss drug market, driven by its in-house semaglutide development, a well-trained medical representative network, and extensive market reach, a top company executive said.

The Mumbai-headquartered company is among the country's top drugmakers that launched generic versions of weight-loss drug semaglutide on Saturday, a day after it lost patent exclusivity in India. Companies including Sun Pharma, Zydus Lifesciences, Natco Pharma and Dr Reddy's Laboratories have all launched generic semaglutide brands priced 50-90% cheaper than the innovator brands - Ozempic and Wegovy developed by Danish drugmaker Novo Nordisk.

Alkem's injectable pen is pr...